Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the
development and sale of broadly enabling, pressure-based instruments,
consumables and platform solutions, this morning announced that President and
CEO Richard T. Schumacher was recently interviewed by broadcast journalist
Christine Corrado of Proactive Investors, a leading multi-media news
organization, investor portal and events management business. During the
interview, Schmacher discussed the two major milestones that the company
recently achieved in its accelerated Ultra Shear Technology (“UST”) development
program, including the completion of development of the first working prototype
of the UST system and the use of this prototype to demonstrate a unique and
profound capability for making high value oil-based materials dissolve in
water. “We are very pleased to have had the opportunity to share the Company’s
recent milestones with a rapidly expanding, worldwide audience of potential
investors, partners, customers, and collaborators,” Jeffrey N. Peterson, board
chairman of PBIO, stated in the news release. “Proactive Investors is a
well-respected, far-reaching multi-media news organization with the ability to
effectively broadcast the corporate stories investors need to hear. We
appreciated the insightful interview opportunity with Christine Corrado and we
hope that many of their viewers will have the opportunity to watch this
milestone interview.”
To view the video interview, visit http://ibn.fm/Q0Fa1
To view the full press release, visit http://ibn.fm/9NxSs
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. The company’s products are based on
the unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions (e.g., cell lysis, biomolecule extraction).
PBIO’s primary focus is in the development of PCT-based products for biomarker
and target discovery, drug design and development, biotherapeutics
characterization and quality control, soil & plant biology, forensics, and
counter-bioterror applications. Additionally, major new market opportunities
have emerged in the use of its pressure-based technologies in the following
areas: (1) the use of its recently acquired PreEMT technology from BaroFold,
Inc. to allow entry into the biologics contract research services sector, and
(2) the use of its recently-patented, scalable, high-efficiency, pressure-based
Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of
otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher
quality, homogenized, extended shelf-life or room temperature stable low-acid
liquid foods that cannot be effectively preserved using existing non-thermal
technologies. For more information, visit the company’s website at www.PressureBiosciences.com
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
